Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):267-78

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather
FREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):267-78

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Targeting the bone marrow: applications in stem cell transplantation

Orchard K. 1, Cooper M. 2

1 Department of Haematology Southampton University Hospitals Trust Southampton, United Kingdom 2 Pharmacy Department St Bartholomew’s Hospital London, United Kingdom


FULL TEXT  


Therapeutic doses of radiation can be selectively directed to the bone marrow either directly using vectors that bind to myeloid and/or lymphoid specific antigens or indirectly by targeting bone matrix. The combination of an accessible target tissue and relatively radiation sensitive malignant cells favours the use of targeted radiotherapy in the treatment of haematopoietic malignancies. Dose escalation of targeted radiation can increase tumour cell destruction and has led to the use of myelosuppressive and possibly myeloablative doses of targeted radiation. A natural development has been the use of targeted radiation in conditioning prior to haematopoietic stem cell transplantation (HSCT). Several groups are actively exploring the use of targeted radiotherapy in the context of HSCT as treatment for haematological malignancies. Although no randomised trials using targeted radiotherapy in HSCT have been published, phase I and II trials have shown very encouraging results stimulating further clinical research in this field. After more than a decade of translational research the optimal combination of therapeutic radioisotope and vector has not been determined. This review summarises the clinical experience of targeted radiotherapy in HSCT and discusses the problems that still need to be solved to maximise the potential of this new treatment modality in HSCT.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail